Probi (OM:PROB) - Aandelenkoers, Nieuws & Analyse

PROB Overzicht aandelen

PROB fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	1/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 62.02% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Probi AB (publ) Concurrenten

Devyser Diagnostics

OM:DVYSR

SEK 2.2b

BioGaia

OM:BIOG B

SEK 10.7b

Egetis Therapeutics

OM:EGTX

SEK 2.0b

Cereno Scientific

OM:CRNO B

SEK 1.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Probi
Historische aandelenkoersen
Huidige aandelenkoers	SEK 351.00
52 Week Hoogtepunt	SEK 351.00
52 Week Laag	SEK 181.00
Bèta	0.46
11 maand verandering	31.46%
3 maanden verandering	31.95%
1 Jaar Verandering	64.02%
33 jaar verandering	-17.31%
5 jaar verandering	48.41%
Verandering sinds IPO	881.82%

Recent nieuws en updates

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Nov 21

Recent updates

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Nov 21

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Jul 24

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Jun 26

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

May 05

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Mar 05

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Feb 15

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

Jan 29

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

Jan 11

Have Insiders Been Buying Probi AB (publ) (STO:PROB) Shares?

Dec 22

Has Probi AB (publ)'s (STO:PROB) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 03

Rendement voor aandeelhouders

	PROB	SE Biotechs	SE Markt
7D	36.0%	2.5%	0.7%
1Y	64.0%	17.7%	12.3%

Rendement versus industrie: PROB overtrof de Swedish Biotechs industrie, die het afgelopen jaar een rendement 17.7 % opleverde.

Rendement versus markt: PROB overtrof de Swedish markt, die het afgelopen jaar een rendement opleverde van 12.3 %.

Prijsvolatiliteit

Is PROB's price volatile compared to industry and market?
PROB volatility
PROB Average Weekly Movement	13.3%
Biotechs Industry Average Movement	9.4%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.4%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: De aandelenkoers van PROB is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van PROB is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Swedish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1991	157	Anita Johansen	www.probi.com

Probi AB (publ) onderzoekt, produceert en verkoopt probiotica voor voedingssupplementen en voedingsmiddelenbedrijven in Noord-Amerika, Zuid-Amerika, Europa, Zweden, het Midden-Oosten, Afrika, Azië-Pacific en internationaal. Het bedrijf voert voornamelijk onderzoek uit op het gebied van mentale gezondheid, spijsvertering, immuunsysteem, botten, orale gezondheid, gezondheid van kinderen, vrouwen en ouderen, evenals ijzerabsorptie. Het bedrijf levert voedingssupplementen, voedingsmiddelen en dranken in de vorm van capsules, tabletten en bolletjes, kauwtabletten, poeder, vruchtendranken, shots, koolzuurhoudende dranken, gekoelde zuivelproducten en producten op basis van planten, diepvriesdesserts en ijs, poedersamenstellingen en hersteldranken.

Probi AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Probi zich tot de beurswaarde?
PROB fundamentele statistieken
Marktkapitalisatie	SEK 4.00b
Inkomsten(TTM)	SEK 10.88m
Inkomsten(TTM)	SEK 630.39m

367.5x

Koers/Winstverhouding

6.3x

P/S-verhouding

Is PROB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PROB resultatenrekening (TTM)
Inkomsten	SEK 630.39m
Kosten van inkomsten	SEK 421.23m
Brutowinst	SEK 209.16m
Overige uitgaven	SEK 198.27m
Inkomsten	SEK 10.88m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Jan 28, 2025

Winst per aandeel (EPS)	0.96
Brutomarge	33.18%
Nettowinstmarge	1.73%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde PROB op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.4%

Huidig dividendrendement

136%

Uitbetalingsratio

PROB Overzicht aandelen

Beloningen

Risicoanalyse

Probi AB (publ) Concurrenten

OM:DVYSR

SEK 2.2b

OM:BIOG B

SEK 10.7b

OM:EGTX

SEK 2.0b

OM:CRNO B

SEK 1.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

New major risk - Share price stability

Now 27% overvalued after recent price rise

Probi AB (publ) Announces CFO Changes

Probi AB Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Recent updates

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

New major risk - Share price stability

Now 27% overvalued after recent price rise

Probi AB (publ) Announces CFO Changes

Probi AB Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Probi AB (Publ) Launches Probi Sense

New minor risk - Share price stability

Now 21% undervalued

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Now 22% undervalued

Now 22% undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Dividend of kr1.30 announced

Now 21% undervalued after recent price drop

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Third quarter 2023 earnings released: EPS: kr0.56 (vs kr1.09 in 3Q 2022)

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Second quarter 2023 earnings released: kr0.55 loss per share (vs kr1.75 profit in 2Q 2022)

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Insufficient new directors

Upcoming dividend of kr1.30 per share at 0.7% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Now 21% undervalued after recent price drop

Probi AB (publ) Announces Management Changes

Now 25% undervalued after recent price drop

Probi Probiotics Reduce Gut Problems in Connection with Cancer Radiotherapy

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Probi AB (Publ) Approves Dividend for the Financial Year 2021

Chief Executive Officer recently bought kr409k worth of stock

Upcoming dividend of kr1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend, Payable on 12 May 2022

Now 23% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend for the Year 2021